-
Dr. Hui Wang: Unlocking a New Approach to MRD Testing in Acute Myeloid Leukemia
The 49th European Bone Marrow Transplantation Annual Meeting (EBMT 2023) took place in Paris, France, from April 23 to 26, 2023. Experts and scholars from various countries gathered to present exciting advancements in research. In the field of blood tests, the fifty-year anniversary of flow cytometry coincided with this year’s conference. Over the past half-century,…
-
Dr. Xingyu Cao: Post-transplant maintenance therapy with Chidamide in T-ALL patients is expected to reduce relapse and improve survival
Acute T-cell lymphoblastic leukemia (T-ALL) is a highly heterogeneous malignant tumor of the hematopoietic system caused by the malignant transformation of T-cell precursors. It has significant differences from B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in clinical features, cellular genetics, molecular biology, and abnormal signal transduction pathways. T-ALL accounts for 10%-15% in children and 20%-25% in…
-
How to choose the maintenance treatment plan after HSCT for R/R malignant hematological patients?
Relapse/refractory (R/R) has always been a difficult point in the clinical treatment of malignant hematological tumors. Hematopoietic stem cell transplantation (HSCT) is an important treatment for these patients to achieve long-term survival. Subsequent maintenance treatment is essential to consolidate the effects of HSCT and prevent disease recurrence. Therefore, researchers have been focusing on optimizing the…
-
ESMO 2023丨Professor Feng Jin: CLEVER Study – Repurposing Old Drugs for Targeting Dormant Tumor Cells to Prevent High-Risk Breast Cancer Recurrence
Editor’s note: Previous studies have indicated a close association between disseminated tumor cells (DTC) in the bone marrow and breast cancer recurrence. At the 2023 ESMO conference, data from the…
-
ESMO 2023 China Voice | Professor Fei Han: Hot Research on Nasopharyngeal Carcinoma in China, Innovative Drug Efficacy Worth Expecting!
Editor’s Note: The ESMO Annual Meeting in 2023 was held grandly in Madrid, Spain, from October 20th to 24th. As an authoritative annual event in the field of oncology, the…
-
ESMO Exclusive Interview | Dr.Changsong Qi: CAR-T Therapy IM96 Shows Significant Antitumor Activity in Advanced Colorectal Cancer with GCC Expression
Phase I study of GCC CAR-T therapy IM96 in patients with advanced colorectal cancer Background The clinical outcomes of metastatic colorectal cancer (mCRC) therapies are limited. Guanylyl cyclase 2C (GCC)…
-
Two renal cancer-related studies by Dr. Kan Gong ‘s team selected for the 2023 EAU Annual Meeting
The 38th European Association of Urology Annual Meeting (EAU23) was held in Milan, Italy, the world’s fashion capital, from March 10 to 13, 2023. The EAU annual conference is one of the most closely watched urology conferences in Europe and even globally, attracting over 15,000 urology experts worldwide every year. At this EAU conference, two…
-
Two Studies of Dr. Yong Xu’s Team at the 2023 EAU Congress, Provided New Insights into Prostate Cancer Biopsies
The 38th Annual Congress of the European Association of Urology (EAU23) took place in Milan, Italy, from March 10 to 13, 2023. EAU Congress is one of the most highly anticipated urology conferences in Europe and worldwide, attracting over 15,000 urology experts from around the globe each year. At this year’s EAU Congress, Dr. Yong…
Connecting Medical Expertise through Media